BioFactura Overview
- Founded
- 2004

- Status
- Private
- Employees
- 30

- Latest Deal Type
- Grant
- Latest Deal Amount
- $482K

- Investors
- 11
BioFactura General Information
Description
Developer of novel drugs designed to create biodefense vaccines and biological drugs against smallpox and Ebola. The company specializes in developing and manufacturing high-value biosimilars, biodefense medical countermeasures, and client-selected novel drugs using its patented StableFast Biomanufacturing Platform, enabling physicians to commercialize products to market with faster, lower cost at superior quality.
Contact Information
- 8435 Progress Drive
- Suite Z
- Frederick, MD 21701
- United States
BioFactura Timeline
BioFactura Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
10. Grant | 01-Jan-2020 | $482K | 00.000 | Completed | Generating Revenue | |
9. Later Stage VC (Series B) | 29-Apr-2019 | 000 | 00.000 | 0000 | Completed | Generating Revenue |
8. Grant | 01-Jan-2018 | 00000 | 00.000 | Completed | Generating Revenue | |
7. Later Stage VC (Series A) | 26-Apr-2016 | 00.000 | 00.000 | 00.00 | Completed | Generating Revenue |
6. Grant | 07-Apr-2016 | 0000 | 0000 | Completed | Generating Revenue | |
5. Accelerator/Incubator | 04-Sep-2015 | 0000 | Completed | Generating Revenue | ||
4. Grant | 15-Sep-2014 | 0000 | Completed | Generating Revenue | ||
3. Grant | 26-Jun-2012 | 00.000 | 0000 | Completed | Generating Revenue | |
2. Accelerator/Incubator | 31-Jan-2006 | $25K | $25K | Completed | Generating Revenue | |
1. Grant | 01-Jan-2006 | $3.07M | Completed | Generating Revenue |
BioFactura Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00.000 | ||
Series A | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
BioFactura Comparisons
Industry
00000
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialBioFactura Competitors (26)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Kymab | Formerly VC-backed | Cambridge, United Kingdom | 000 | 00000 | 000000&0 | 00000 |
00000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000000 | 00000 |
00000 000000000000 | Venture Capital-Backed | Didcot, United Kingdom | 0 | 00000 | 0000000000 0 | 00000 |
0000000 00000000 | Formerly VC-backed | Alpharetta, GA | 000 | 00000 | 000000 - 000 | 00000 |
00000000 000000000 | Formerly VC-backed | Carmiel, Israel | 000 | 00000 | 000000000 | 00000 |
BioFactura Patents
BioFactura Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-2406367-A4 | Separation of antigen-specific memory b cells with a conjugated biopolymer surface | Granted | 09-Mar-2009 | 000000000 | 0 |
US-20120045827-A1 | Separation of antigen-specific memory b cells with a conjugated biopolymer surface | Abandoned | 09-Mar-2009 | 000000000 | 0 |
EP-2406367-A2 | Separation of antigen-specific memory b cells with a conjugated biopolymer surface | Granted | 09-Mar-2009 | 000000000 | 0 |
EP-2406367-B1 | Separation of antigen-specific memory b cells with a conjugated biopolymer surface | Expired - Fee Related | 09-Mar-2009 | 000000000 | |
CA-2792709-A1 | Separation of antigen-specific memory b cells with a conjugated biopolymer surface | Granted | 09-Mar-2009 | C12M47/04 |
BioFactura Executive Team (4)
BioFactura Board Members (5)
Name | Representing | Role | Since |
---|---|---|---|
Alex DeSeabra | BioFactura | Co-founder, Board Member & Consultant | 000 0000 |
Darryl Sampey Ph.D | BioFactura | Chief Executive Officer, President, Board Member, Chief Scientific Officer and Co-Founder | 000 0000 |
Dominic Eisinger Ph.D | Self | Board Member | 000 0000 |
Jeffrey Hausfeld MD | BioFactura | Chief Medical Officer & Chairman | 000 0000 |
BioFactura Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialBioFactura Investors (11)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
University Of Vermont Health Network | Corporation | Minority | 000 0000 | 000000 0 | |
Wilson Sonsini Goodrich & Rosati | Corporation | Minority | 000 0000 | 000000 0 | |
Jeffrey Hausfeld | Angel (individual) | Minority | 000 0000 | 000000 0 | |
Maryland Department of Commerce | Government | 000 0000 | 000000 0 | ||
St. Louis Development | Lender/Debt Provider | Minority | 000 0000 | 000000 0 |